Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
September 25, 2017 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that new data from its omadacycline clinical and microbiology programs will be presented at...
Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections
September 21, 2017 08:00 ET
|
Paratek Pharmaceuticals
Uncomplicated UTIs are among the most common bacterial infections with few oral treatment options BOSTON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a...
Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017
September 19, 2017 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 01, 2017 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
August 22, 2017 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that the Company will participate in five upcoming investor conferences. Paratek is a...
Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference
August 08, 2017 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President, Chief Operating Officer and Chief Medical Officer, Evan Loh, MD, will...
Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update
August 02, 2017 07:00 ET
|
Paratek Pharmaceuticals
Clinical program successfully completed to support regulatory applications and potential approval in the U.S. and EUPre-NDA meetings with FDA confirm clear path to submissionRolling submission of NDA...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 01, 2017 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017
July 19, 2017 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, July 19, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
July 17, 2017 16:01 ET
|
Paratek Pharmaceuticals
Omadacycline generally safe and well toleratedCompany on track to file NDAs with FDA as early as 1Q 2018Webcast and conference call for investors at 4:30 p.m. today EDT to review top-line results ...